Therapeutic Monitoring Of Vancomycin For Serious Methicillin-Resistant Staphylococcus Aureus Infections

Publication Date: March 19, 2020
Last Updated: March 14, 2022

Recommendations

Therapeutic Monitoring

1. In patients with suspected or definitive serious MRSA infections, an individualized target of the AUC/MICBMD ratio of 400 to 600 (assuming a vancomycin MICBMD of 1 mg/L) should be advocated to achieve clinical efficacy while improving patient safety. ( A , II )
686
Doses of 15 to 20 mg/kg (based on actual body weight) administered every 8 to 12 hours as an intermittent infusion are recommended for most patients with normal renal function when assuming a MICBMD of 1 mg/L. ( A , II )
686

Overview

Title

Therapeutic Monitoring Of Vancomycin For Serious Methicillin-Resistant Staphylococcus Aureus Infections

Authoring Organizations

American Society of Health-System Pharmacists

Infectious Diseases Society of America

Society for Healthcare Epidemiology of America

Surgical Infection Society